



## POLYCHLORINATED BIPHENYLS AND POLYBROMINATED BIPHENYLS

VOLUME 107

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 12–19 February 2013

Lyon, France - 2016

IARC MONOGRAPHS  
ON THE EVALUATION  
OF CARCINOGENIC RISKS  
TO HUMANS

# CONTENTS

---

<b>NOTE TO THE READER</b> .....	<b>1</b>
<b>LIST OF PARTICIPANTS</b> .....	<b>3</b>
<b>PREAMBLE</b> .....	<b>9</b>
<b>A. GENERAL PRINCIPLES AND PROCEDURES</b> .....	<b>9</b>
1. Background .....	9
2. Objective and scope .....	10
3. Selection of agents for review .....	11
4. Data for the <i>Monographs</i> .....	11
5. Meeting participants .....	12
6. Working procedures .....	13
<b>B. SCIENTIFIC REVIEW AND EVALUATION</b> .....	<b>14</b>
1. Exposure data .....	15
2. Studies of cancer in humans .....	16
3. Studies of cancer in experimental animals .....	20
4. Mechanistic and other relevant data .....	23
5. Summary .....	26
6. Evaluation and rationale .....	27
References .....	31
<b>GENERAL REMARKS</b> .....	<b>33</b>
 <b>POLYCHLORINATED BIPHENYLS</b>	
<b>1. EXPOSURE DATA</b> .....	<b>41</b>
1.1 Identification of the agent .....	41
1.2 Analysis .....	60
1.3 Production and uses .....	70
1.4 Environmental occurrence and exposure .....	74
1.5 Occupational exposure to PCBs .....	117

---

1.6	Exposure assessment of epidemiological studies	128
1.7	Regulations and guidelines	130
<b>2.</b>	<b>CANCER IN HUMANS</b>	<b>165</b>
2.1	Cohort studies of occupational exposure	165
2.2	Cohort studies of environmental exposure	182
2.3	Case-control studies of occupational and environmental exposure	216
<b>3.</b>	<b>CANCER IN EXPERIMENTAL ANIMALS</b>	<b>259</b>
3.1	Oral administration	259
3.2	Transplacental and perinatal exposure	281
3.3	Initiation-promotion and co-carcinogenicity studies	293
<b>4.</b>	<b>MECHANISTIC AND OTHER RELEVANT DATA</b>	<b>313</b>
4.1	Absorption, distribution, metabolism, and excretion	313
4.2	Genetic and related effects	328
4.3	Biochemical and cellular effects	354
4.4	Organ toxicity relevant to carcinogenicity	379
4.5	Susceptibility	386
4.6	Mechanistic considerations	390
<b>5.</b>	<b>SUMMARY OF DATA REPORTED</b>	<b>423</b>
5.1	Exposure data	423
5.2	Human carcinogenicity data	425
5.3	Animal carcinogenicity data	427
5.4	Mechanistic and other relevant data	430
<b>6.</b>	<b>EVALUATION AND RATIONALE</b>	<b>439</b>
6.1	Cancer in humans	439
6.2	Cancer in experimental animals	439
6.3	Overall evaluation	439
6.4	Rationale	439
 <b>POLYBROMINATED BIPHENYLS</b>		
<b>POLYBROMINATED BIPHENYLS</b>		
<b>1.</b>	<b>Exposure Data</b>	<b>443</b>
1.1	Identification of the agents	443
1.2	Analysis	451
1.3	Production and uses	453

1.4	Environmental occurrence and human exposure	454
1.5	Occupational exposure	464
1.6	Regulations and guidelines	468
2.	Cancer in Humans	468
3.	Cancer in Experimental Animals	469
3.1	Mouse	469
3.2	Rat	476
3.3	Hamster	484
4.	Mechanistic and Other Relevant Data	485
4.1	Absorption, distribution, metabolism, and excretion	485
4.2	Genetic and related effects	486
4.3	Biochemical and cellular effects	486
4.4	Organ toxicity	488
4.5	Mechanistic considerations	489
5.	Summary of Data Reported	490
5.1	Exposure data	490
5.2	Human carcinogenicity data	490
5.3	Animal carcinogenicity data	490
5.4	Mechanistic and other relevant data	491
6.	Evaluation	492
6.1	Cancer in humans	492
6.2	Cancer in experimental animals	492
6.3	Overall evaluation	492
<b>LIST OF ABBREVIATIONS</b>		<b>501</b>

## NOTE TO THE READER

---

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.